ArticleFrontiers in oncology2026
Matrix metalloproteinase expression in basal cell carcinoma, squamous carcinoma, and melanoma: diagnostic and prognostic potential.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Skin cancer, including basal cell carcinoma, squamous cell carcinoma, and melanoma, is one of the most common cancers worldwide. Matrix metalloproteinases are zinc-dependent proteolytic enzymes that play a crucial role in tumor invasion and angiogenesis by degrading the extracellular matrix. This study aims to analyze the specific expression of three matrix metalloproteinases (MMP-3, MMP-9, and MMP-14) to better understand the molecular mechanisms underlying the invasiveness of different skin cancer subtypes. Methods: The study involved 30 patients aged between 40 and 50 years: 10 diagnosed with BCC, 10 with SCC, and 10 with melanoma. A control group of 10 normal skin samples was also used. All tumor samples were selected from non-invasive, well-differentiated forms. The expression of MMP-3, MMP-9, and MMP-14 was detected using immunohistochemistry on deparaffinized tissue sections. Results: The IHC analysis revealed distinct expression patterns across the subtypes:Basal cell carcinoma: MMP-3 and MMP-14 were strongly expressed with both nuclear and cytoplasmic localization. MMP-9 expression was notably lower and limited to specific cells in the basal layersSquamous cell carcinoma: Only weak and diffuse cytoplasmic expression of MMP-14 was identified in the epidermal layers. MMP-3 and MMP-9 were completely absent.Melanoma: All three MMPs were highly expressed, exhibiting intense cytoplasmic and nuclear localization. MMP-3 and MMP-14 showed increased expression alongside significantly altered cellular architecture. Discussion: The differential findings suggest that MMP expression reflects the biological behavior and metastatic potential of each tumor. In Basal cell carcinoma, the significant expression of MMP-3 and MMP-14 suggests involvement in local proliferation and stromal remodeling rather than high metastatic capacity. The absence of MMPs in Squamous cell carcinoma may be due to intense keratinization and a loss of metabolic function in these tumor cells. In melanoma, the high expression of all three enzymes confirms their significant role in aggressive invasion and angiogenesis. Conclusion: MMP-3 and MMP-14 may serve as valuable diagnostic and prognostic biomarkers, as well as potential therapeutic targets for skin cancer management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.